Member Login
  1. Stocks
    2. /
  2. Bausch Health Companies Inc. (NYSE: BHC)
    3. /

NYSE:BHC (Bausch Health Companies Inc.)

About BHC

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Bausch Health Companies Inc. (NYSE: BHC) Latest News

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Is This Stock Worth a Contrarian Shot for 2017?

    | Andrew Walker

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a seriously unloved stock. Is it finally time to buy?

    Read more »

    Investing

    Will Canopy Growth Corp. Crash as Hard as Valeant Pharmaceuticals Intl Inc.?

    | Joey Frenette

    Canopy Growth Corp. (TSX:CGC) has been falling hard over the last week. Will this company face the same fate as…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Has This Stock Finally Hit Bottom?

    | Andrew Walker

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is getting a nice post-election bounce. Is this the time to buy?

    Read more »

    The Motley Fool
    Investing

    Why Bill Ackman Should Give Up on Valeant Pharmaceuticals Intl Inc.

    | Joey Frenette

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) reported a horrible quarter, and the stock responded by dropping. Bill Ackman still believes in…

    Read more »

    Investing

    3 TSX “Loser” Stocks to Bet on

    | Will Ashworth

    A total of 32 TSX stocks are down by more than 5% year-to-date, including Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), the…

    Read more »

    Investing

    Long-Term Investors: Valeant Pharmaceuticals Intl Inc. Looks to Ease Debt Burden

    | Chris MacDonald

    Valeant Pharmaceuticals Intl Inc.'s (TSX:VRX)(NYSE:VRX) sale of its Salix drug business has the potential for great long-term gains for investors…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Drops After Q3 Results Disappoint

    | Demetris Afxentiou

    Troubles continue for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) as the company posts worse than expected results.

    Read more »

    The Motley Fool
    Investing

    Should You Buy Valeant Pharmaceuticals Intl Inc. After its 22% Plunge?

    | Joey Frenette

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) took a huge hit in its latest earnings report, and the stock responded by dropping…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Should You Try to Catch This Falling Knife?

    | Andrew Walker

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) just reminded investors that cheap stocks can get a lot cheaper very quickly.

    Read more »

    The Motley Fool
    Dividend Stocks

    3 Canadian Stocks to Buy in a Donald Trump World

    | Nelson Smith

    A Trump presidency is good news for TransCanada Corporation (TSX:TRP)(NYSE:TRP), Barrick Gold Corp. (TSX:ABX)(NYSE:ABX), and one other stock.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Is in Trouble Again: Down 25%

    | Ryan Vanzo

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a lottery ticket with huge upside and downside potential.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals International Inc. Q3 Earnings Preview: It’s Gonna Be Ugly

    | Alexander John Tun

    What to expect from the market's most beaten-up stock, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) next Tuesday.

    Read more »